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Clinical CRISPR Outlook

Abstract:
Gene editing capabilities have expanded enormously since researchers first demonstrated the
robust, accurate, and efficient endonuclease activity of the CRISPR/Cas riboprotein enzyme.
Since this gene editing technique was first described in 2013, the prospect of gene therapy as a
viable clinical tool has improved immensely. CRISPR/Cas techniques and the methods by which
they are delivered into cells, have evolved rapidly since the technology s inception, and
successful, intentional genetic alterations of numerous mammalian cell lines have been reported.
As a research tool, CRISPR/Cas9 has already proven itself indispensable in a brief period of
time. While there are not numerous clinical trials involving CRISPR/Cas technology, CRISPR
has absolutely contributed to the acceleration and expansion of gene therapy-based clinical trials
in the past five years. Here, the current capabilities of CRISPR/Cas gene editing are evaluated as
they relate to the clinical setting, including potential for CRISPR/Cas to function as: a new
cancer therapeutic agent, a means of correcting or relieving genetic disease, and a potent
disrupter of antimicrobial resistance genes in virulent MDR bacterial strains. Additionally, the
future possibilities of CRISPR/Cas-related therapies, and issues preventing the achievement of
these therapies in the clinical setting, are discussed.
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Introduction:
In late 2017, Brian Madeux, an American man with the inherited genetic disorder of Hunter s
syndrome, received a novel treatment at the Benioff Children s Hospital at the University of
California–San Francisco – in vivo genetic editing, via the delivery of zinc finger nucleases
(ZFNs) – to treat his disease. This represented the first report in the world describing the
treatment of genetic diseases through in vivo gene editing, demonstrating that gene editing has
important clinical potential for the treatment of genetic diseases 1. Since that time, a new gene
editing technique called CRISPR/Cas has emerged as an invaluable research technology, having
been utilized in numerous clinical trials for the treatment of diseases including, but not limited
to: sickle cell disease, Beta-thalassemia, heritable cardiomyopathies, lymphomas, melanomas,
and viral infections such as HIV and Hepatitis B.
Researchers have known for decades that the genomes of bacteria and archaea housed
sequences of bacteriophage DNA in patterns of clustered, regularly-interspaced palindromic
repeats (CRISPR). These CRISPR segments, along with the CRISPR-associated (Cas) family of
endonuclease enzymes, were understood to be a secondary microbial defense mechanism against
invading bacteriophage viruses. Specifically, CRISPR/Cas9 is a type II acquired immune system
in bacteria and archaea, and it serves to fend off cellular invaders by destroying bacteriophage
DNA/RNA that a given phage has injected into the host microbe2,3. After destroying an invading
bacteriophage, a bacterium can incorporate into its o n DNA a small portion of the phage s
DNA, and the incorporated phage DNA is thereafter termed a spacer . While DNA normall
acts primarily as a template for DNA replication or protein synthesis, the phage DNA spacer is
transcribed into RNA and embedded within a Cas protein where it functions as a template for
DNA destruction. In short, the spacer within the bacterial genome enables the host bacteria to
2
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quickly recognize and defend against bacteriophage infections. A helpful analogy would be to
think of a given Cas protein as a police officer, the CRISPR locus on a bacterial chromosome as
a series of mugshots, and cytosolic DNA or RNA as a criminal suspect; as the Cas enzyme (the
officer) compares free-floating DNA or RNA (suspects) to the spacer-derived RNA (the
mugshot), it can recognize and neutralize dangero s s spects before any damage is done.
Cas enzymes need a guide RNA to specify their target. Naturally occurring Cas enzymes
within microbes require two RNA sequences: trans-activating CRISPR RNA (tracrRNA) which
enables Cas endonuclease activity, and CRISPR RNA (crRNA) which is derived from the spacer
and provides the template with which the Cas enzyme targets a specific bacteriophage DNA
sequence3. Natural Cas proteins destroy invading DNA by inducing a double strand break (DSB)
in the foreign DNA sequence specified by guide RNA, after guide RNA dimerization with the
exogenous target DNA4.
In the laboratory, the same principle applies but with a custom-made synthetic single guide
RNA (sgRNA), which is essentially a fusion of the tracrRNA and crRNA (Figure 1) 5,6. In most
cells, eukaryotic or prokaryotic, most DSB events are followed by cell-mediated DNA repair,
which occurs in either an error-free pathway of Homology Directed Repair (HDR) or an errorprone Non-Homologous End-Joining (NHEJ) pathway7,8. The HDR pathway typically uses a
sister chromatid as a template to repair a damaged gene segment in eukaryotic cells, thereby
restoring the gene and its function. Repair by NHEJ, however, commonly features loss of
nucleotides on either side of the DSB during the repair process, so when ligation finally occurs,
the restored chromosome has either lost or needlessly added some genetic information; this
introduces a nonsense mutation into the gene about 67% of the time, effectively knocking-out the
gene by irreversibly altering the coding sequence8 (Figure 2). NHEJ repair of a DSB can occur at
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any time, but error-free HDR is isolated to G2 and S phases of the cell cycle9. While there are
exceptions, CRISPR/Cas techniques that integrate an exogenous gene of interest into a host
genome – i.e. a genetic knock-in event – generally rely on the HDR pathway for integration, but
rely on the error-prone NHEJ pathway when CRISPR/Cas is utilized to knock-out an
endogenous gene.
The first reports of researchers successfully modifying mammalian cells with CRISPR-Cas9
technology were published in 2013 by Jennifer Doudna s lab at University of California,
Berkeley1. Since then, CRISPR/Cas technology has become a linchpin method for genetic
research in laboratories all over the world and has supplanted previously popular enzyme-based
genetic modification procedures such as Transcription Activator-Like Effector Nucleases
(TALEN) and the previously mentioned ZFNs10,11.
One main reason CRISPR-Cas9 is currently in vogue among researchers is due to its
flexibility and elegant mechanism of action. Proteins are responsible for the enzymatic induction
of DNA double-strand breaks (DSBs) in the CRISPR/Cas, ZFN, and TALEN gene-editing
systems alike. In the ZFN and TALEN systems, proteins are also responsible for recognizing the
correct target DNA sequence; contrast that with the CRISPR/Cas, wherein RNA is responsible
for recognizing the correct DNA sequence11 (Figure 3). Because targeting a new DNA sequence
depends on protein alterations in the ZFN-based and TALEN-based nuclease systems, they both
require extensive re-engineering for every unique DNA sequence they target. Changing the
constituent proteins in ZFN and TALEN systems is somewhat fickle, and though ZFN and
TALEN are well-studied, each modification can have unintended consequences that reduce their
enzymatic efficiency or accuracy. Consequently, the re-designing process for ZFN and TALEN
systems is time consuming, costly, somewhat unpredictable, and labor intensive.
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The Cas family of enzymes, however, do not require any modifications to induce a DSB at a
given sequence. Instead, a sgRNA embedded within the Cas enzyme recognizes and binds a
complimentary DNA sequence, and the resultant extrinsic-DNA/intrinsic-RNA heterodimer
triggers Cas-mediated DSB induction in the target DNA strand by hydrolyzing the covalent
bonds on the target DNA phosphate backbone (Figures 1 and 3). Because the Cas protein isn t
responsible for recognizing the target DNA, it doesn t need any alterations for each unique target
sequence. Changing the sgRNA is more affordable and substantially easier than altering proteins,
which makes CRISPR/Cas, for all practical purposes, a more versatile tool than either ZFN or
TALEN systems. Furthermore, one major advantage of CRISPR/Cas9 is its potential for
simultaneous editing at multiple genetic loci by simply transfecting multiple sgRNA molecules
into a target cell1. It is not hyperbole to proclaim CRISPR-Cas9 as an indispensable, state-of-theart system in biochemical research with immense potential for translation into the clinic.
Since the advent of CRISPR-Cas9, clinical trials involving some degree of genetic
modifications have accelerated remarkably. Per Hirakawa et al., only one clinical trial involving
genetic modification was registered in 2009 and two or fewer such trials were registered per year
from 2010 through 2015. In 2016, three years after the CRISPR-Cas9 system was described as
an efficient gene-editing tool, the number of clinical trials utilizing genome editing technology
increased to ten. There were another ten such new trials registered in 2017, and 13 registered in
2018. Additionally, it is noteworthy that ZFN s had been the genetic modification technique of
choice prior to 2016 but since then, CRISPR-Cas9 and TALEN gene-editing techniques have
dominated the field5.
While the outlook for CRISPR/Cas in the clinical setting is certainly promising, researchers
are still studying and testing this relatively young genetic tool. Safety and efficacy determine the
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viability of any treatment, and they are doubly important in gene therapy, as any genetic
alterations created, beneficial or deleterious, will become permanent fixtures in all affected cells
and their progeny. If reasonable safety can be demonstrated, the effectiveness of CIRSPR/Cas
relative to other available treatments will further inform whether the risk:reward ratio favors this
new gene-therapy technique. In short, how would a CRISPR/Cas therapy improve upon or
augment existing treatments for diseases, and what progress has been achieved in making
CRISPR/Cas a clinical reality? Additionally, as this technology is still in its relative infancy,
what known limitations currently inhibit CRISPR/Cas utilization as a clinical therapy?

Background:
Infectious Disease
Despite a concerted shift towards antibiotic stewardship in healthcare, with emphasis on
responsible prescribing practices, antibiotics continue to be overprescribed. The development of
new antimicrobial chemicals, meanwhile, has unfortunately stalled12. As a gene-targeting tool,
successfully ablating antimicrobial resistance (AMR) genes could make CRISPR/Cas a vital
instrument in counteracting the dangers of antimicrobial overprescribing and reinstating
susceptibility to entire strains of microbes, and recent findings have demonstrated the possibility
of CRISPR technologies aiding in the ongoing fight against drug-resistant bacteria in medicine.
The methodology by which CRISPR/Cas could curb the spread of bacteria exhibiting
antimicrobial resistance (AMR) is straightforward: design an AMR-targeting sgRNA and
administer it, along with the Cas enzyme, into the appropriate resistant bacterial population to resensitize the strain to antibiotics. Bikard et al. first described attempts to disrupt AMR genes via
CRISPR/Cas in strains of methicillin-resistant Staphylococcus Aureus (MRSA) and tetracycline-
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resistant Staph Aureus. Previous research indicated that lytic bacteriophages may be a potent
strategy against drug-resistant bacteria. But lytic phages, which kill bacteria en masse, create a
selective stress that almost invariably generates an escape mutation in the targeted bacteria; as a
result, the mutated bacterial population ultimately rebounds, and the phage lethality decreases
against the new mutant bacterial strain10. Moreover, there is a real concern that the phage may
also target normal flora that are vital to the host s normal physiologic functions.
To investigate CRISPR/Cas efficacy for destroying AMR genes, Bikard et al treated
tetracycline-resistant bacteria with a CRISPR/Cas construct targeting the Tetracycline-resistance
gene, using a phagemid vector for delivery; a phagemid is a plasmid enveloped within a
bacteriophage lipoprotein capsid. This system demonstrated selective in vitro cell death among
virulent bacteria with AMR genes for Tetracycline, within a mixed population (Figure 4), and
produced no evidence of significant death among avirulent bacteria. These findings support this
initial proof-of-concept experimentation that phagemid packaging of anti-AMR CRISPR/Cas
could induce cell death among drug-resistant virulent bacteria while sparing normal flora. Using
a phagemid as the vehicle for CRISPR-Cas delivery is not without its own drawbacks and
limitations, and researchers noted that the “main obstacle to translation of this technology into a
viable therapeutic is the efficient delivery of the Cas9 and its RNA guide(s) into bacterial cells”
in vivo13.
Bikard et al argue the advantages of CRISPR/Cas over lytic phage therapy, but recent
publications describe a new hybrid model which hinges upon temperate phages (non-lytic)
imbued with a sgRNA-CRISPR/Cas cassette targeting AMR genes. This hybrid phageCRISPR/Cas system could combine the best of both individual strategies while also mitigating
their shortcomings. Such a Phage-Derived CRISPR/Cas (PDC) system would theoretically have
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minimal risk for off-target effects against a patient, as bacteriophage exclusively target microbes,
not eukaryotic cells, and would spare the avirulent normal flora microbiome.
Liu et al., who studied the possibility of a PDC system featuring a CRISPR/Cas cassette
delivered by temperate bacteriophage, published encouraging results for combatting
antimicrobial resistance as well. They reported successful incorporation of a CRISPR/Cas
cassette into a phage vector, and a follow-up experiment demonstrated efficient eradication of a
kanamycin resistance gene within bacteria following treatment with the PDC construct.
Following destruction of the kanamycin-resistance gene, previously-resistant E. coli bacteria
demonstrated re-sensitization to kanamycin. In total, nine E. coli host strains were transformed
with a PDC construct (targeting kanamycin resistance genes) to test the efficacy of the modified
phage to eliminate resistance plasmids. Bacterial re-sensitization to kanamycin was confirmed in
all strains via genetic screening after treatment with the PDC construct, followed by observance
of in vitro bacterial death upon treatment with Kanamycin to complete this method of Phagedelivered Resistance-Eradication with Subsequent Antibiotic (PRESA) treatment. No subsequent
resistance to the antimicrobial agents or to the phage delivery system was observed10.
To investigate this PRESA strategy in vivo, immunodeficient mice were inoculated with a
kanamycin-resistant E. coli strain on their skin and intestinal surfaces. Twelve hours following
PDC treatment of skin-inoculated mice, only 6.67% bacterial cells isolated from the infection
site retained a functional copy of the kanamycin resistance gene, markedly lower than the
98.33% antimicrobial gene retention rate observed in the control group (Figure 5). The
intestinally inoculated mice treated with the PRESA method also exhibited significant
destruction of the antimicrobial gene. The intestinal E. coli exhibited persistent kanamycin resensitization throughout the time course of the experiment. Again, no resistant mutants to the

8

Clinical CRISPR Outlook

PDC or PRESA methods were observed. This novel PRESA strategy efficiently induced
antimicrobial re-sensitization with subsequent bacterial death upon kanamycin treatment and
yielded no new resistant mutants10.
Destruction of resistance genes is arguably as important as killing the virulent bacteria that
utilize them, because resistance genes are most often transferred between microbes via circular
plasmid DNA, and don t incorporate into the host microbe s chromosomes. So, even if a microbe
is killed, its AMR genes may persist and transform a naïve bacterium into a resistant strain.
Enzymatically active CRISPR/Cas riboproteins with isoforms Cas9 and Cas3 had previously
failed to demonstrate any significant endonuclease activity against bacterial plasmids14.
Complexes featuring the Cas13 isoform, however, fulfill a different niche role in secondary
bacterial immunity: while Cas9 and Cas3 proteins can only target either free floating
bacteriophage RNA or chromosomal phage genes, CRISPR-Cas13 complexes can create DSB s
within both chromosomal and plasmid DNA14. Evolutionarily, this activity of Cas13 helps a
microbe defend against temperate bacteriophage genes that have, by chance, integrated into
plasmid DNA. So, while Cas9 and Cas3 can only disrupt chromosomal phage DNA, or actively
invading phage DNA/RNA, Cas13 can destroy targets on bacterial plasmids in addition to
bacterial chromosomes. Cas13 therefore could exhibit more-widespread activity for neutralizing
AMR genes.
In their recent paper, Kiga et al (2020) evince the potential of CRISPR/Cas to combat drugresistant bacteria both in vitro and in vivo with a CRISPR sgRNA targeting plasmid-bound AMR
genes in E. coli. Their published findings demonstrate 1) in vitro Cas13-mediated DSB induction
in plasmids featuring the blaIMP-1 AMR gene conferring carbapenem resistance, 2) successful
packaging of the CRISPR-Cas13 construct within a phage capsid for delivery into bacterial

9

Clinical CRISPR Outlook

cytosol, 3) Bactericidal activity of the blaIMP-1 targeting CRISPR-Cas13 construct in vitro, 4)
bactericidal activity of the same CRISPR-Cas13 construct in vivo. The lattermost finding was
achieved by inoculating larvae of the wax moth Galleria mellonella with carbapenem-resistant
E. coli. Carbapenem resistance was conferred on E. coli via a plasmid-bound blaIMP-1 gene, and
administration of a CRISPR-Cas13 construct targeting the blaIMP-1 gene was strongly associated
with increased larvae survival following subsequent carbapenem treatment (Figure 6).

Cancer and Immunotherapy
Cancer is essentially the unchecked growth of a person s own cells. Our genome encodes
numerous proteins for preventing uncontrolled growth and for recognizing and eliminating cells
that are exhibiting cancerous growth behavior. If a protein functions in intercellular
communication, cell-cycle regulation, DNA repair, anti-tumor immune response, or some other
anti-cancer role, a mutation causing deviant activity could permit cancerous growth. Mutations in
one of two broad genetic categories in particular – oncogenes or tumor suppressor genes (TSG) –
can drive cancer. Wild-type oncogene proteins promote cell growth and mitosis, but are subject
to careful control, so mutations that yield constitutively active oncogenes could drive
tumorigenesis. Conversely, TSGs suppresses growth and mitosis, especially when DNA damage
is detected, so a mutant TSG could fail to curb inappropriate cellular growth16.
There are several important milestones that a nascent cancer must achieve before it is
considered malignant or concerning. Two major steps in cancer development involve escape
from host immune surveillance and attaining immortality16. Because mutations induce these
steps towards tumorigenesis, genetic alterations that remove or nullify these via CRISPR/Cas is a
promising option for the future of cancer therapy.
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The natural obstacle preventing cancer cell immortalization involves chromosomal
telomeres, a unique structure in eukaryotic chromosomes that is key for chromosomal integrity.
Telomeres are the distal-most ends of chromosomes; they feature numerous repeats of a
nucleotide motif (5 -TTAGGG-3 ) and have a 3 overhang which performs a strand invasion into
an upstream telomere segment to provide a protective cap on the ends of chromosomes16 (Figure
7). With every mitotic cycle, the telomeres become shorter and shorter until, after approximately
40 cycles, the telomeres are too short for cell viability, causing the cells to enter either
senescence or experience an event called “crisis”. Senescence, the much more common pathway,
is characterized by both cell cycle arrest and the end of cellular division for the senesced cell.
When short telomeres incite crisis, the chromosomes lose their protective telomeric cap,
chromosome fusions occur, and irreparable genomic instability results, effectively ending the
cell s mitotic potential and frequently causing apoptosis16.
A common means of avoiding or overcoming either senescence or crisis involves activating
the telomere-lengthening enzyme Telomerase. Telomerase is a ribonucleoprotein with two
important subunits: an RNA subunit encoded by the TERC gene, and a reverse transcriptase
(RT) which is encoded by the TERT gene. The RT subunit uses the RNA subunit as a template
for elongating telomeres. The enzyme is active only in germ-line cells – sperm and ovum – in
humans. As TERT is suppressed in non-cancerous somatic cell, and normal somatic cells
telomeres shorten with each mitotic cycle as a result, TERT could be considered an oncogene
that drives cancer proliferation when constitutively active by promoting immortalization17.
Current data suggest that 80-90% of cancer cells fail to repress TERT, allowing for telomere
elongation and subsequent avoidance of senescence and crisis 17. As a common feature of cancer
cells, specific TERT/telomerase targeting is a potential target for cancer therapy. It is worth
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noting that an alternative pathway for escaping senescence and crisis exists which involves
spontaneous NHEJ-mediated fusion of uncapped telomeres, but this is much less common and
involves a complex interplay between DNA repair proteins 8,16. Telomerase, conversely, is a
single enzyme that, due to its ubiquity in cancer cells, is a prime target for anti-cancer
CRISPR/Cas therapy.
Wen et al. report successful disruption of the TERT gene via CRISPR-Cas endonuclease
activity, which was achieved in vitro with no off-target mutations detected. Additionally, in vitro
growth was significantly stymied by CRISPR/Cas-mediated mono-allelic TERT knockout,
demonstrating that inducing TERT haploinsufficiency may be adequate for preventing telomere
elongation and could indeed serve as a powerful method for slow tumor growth/progression. To
investigate the effect of TERT haploinsufficiency in vivo, immunodeficient mice underwent hind
leg grafting with Hela cells: the left hind leg of each mouse was grafted with Hela WT cells
(WTPE) and the right hind leg was grafted with Hela cells with sequence-confirmed TERT
haploinsufficiency. The WTPE group developed tumor growth in all animals, while grafting of
the experimental TERT haploinsufficient cells failed to develop any tumor growth in all subjects.
These results further demonstrate the potential of CRISPR/Cas-based therapies to suppress tumor
growth by inducing TERT haploinsufficiency (Figure 8).
In addition to immortalization, long-term survival of a neoplasm also depends on avoiding
detection and destruction by the host immune system. T-cells, specifically, are a major force in
defending against growing cancers, and patients whose cancers are poorly detected by host Tcells are associated with worse outcomes. Harvesting T-cell progenitors, genetically augmenting
them to recognize cancers, and subsequently infusing the altered T-Cells is a promising avenue
of CRISPR/Cas research. Chimeric antigen receptors (CAR) are cell-surface proteins that have

12

Clinical CRISPR Outlook

been engineered to recognize antigens that are commonly associated with tumors; they are
termed chimeric because they exhibit a tandem of antigen recognition and T-cell activating
functions. T-cells with CAR proteins (termed CAR-T cells) have repeatedly demonstrated
promise as a therapeutic adjunct, but engineering them is a difficult process with significant
hurdles to overcome before this theoretical experimental treatment can enter the clinic18,19.
Most CAR-T clinical trials practice transfusion of autologous cells that had previously been
harvested and genetically edited. This ex vivo practice is both time consuming and expensive,
two factors that could limit the potential of CAR-T therapy. A hypothetical allogenic line of
CAR-T cells, derived from one donor and readily available to patients “off the shelf”, would
potentially lower costs, decrease time between diagnosis and treatment, and almost certainly
benefit more people than a practice of autologous modified cells alone. The potential of Graft
Versus Host Disease (GVHD) is preventing such an off the shelf CAR-T cell therapy from
becoming a reality; innate proteins of the allogenic CAR-T cells host could either recognize the
recipient as foreign, or the recipient s immune system may recognize the donor s innate
antigens18, and either manifestation of GVHD would severely undermine the prospect of an “off
the shelf” allogenic CAR-T cell therapy.
The primary feature of developing CAR-T therapy, as discussed, involves equipping cells
with a gene that will improve a patient s tumor suppression capabilities, but minimizing
problematic antigens within the donor T-cells also appears to be a necessary step for achieving
allogenic CAR-T cell therapies. As mentioned above, a CRISPR/Cas mediated DSB can ablate
genetic function when the DSB is followed by error-prone NHEJ DNA repair. It appears that
CRISPR/Cas, in addition to facilitating the addition of a tumor-recognizing CAR gene, may also
be necessary for minimizing GVHD by knocking out endogenous cell-surface proteins18.
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Immunotherapy with CAR-T cells is further limited by data demonstrating little to no effect
in treatment of solid tumors. A complicated interplay of inhibitory factors constituent to the
tumor microenvironment are likely partially responsible for this low observed efficacy, but
CAR-T cells, like all T-cells, can be especially hampered by a process called “exhaustion”.
During T-cell exhaustion, the intercellular functions of T-cells are depressed, while expression of
inhibitory receptors simultaneously increase, further diminishing T-cell function. Exhaustion
ultimately causes apoptosis, and a major mediator of this exhaustion-apoptosis sequence is the
Fas gene. Preventing either CAR-T exhaustion or cell inhibition by inhibiting Fas function could
expand the utility of CAR-T cells if/when they are ever utilized clinically18. In short: multiple
genetic alterations are required to attain “off the shelf” CAR-T cells.
Ren et al. reported the successful ablation of genes encoding cell surface proteins CD3 and
HLA-1, as well as the apoptosis-promoting Fas gene, with a one-shot CRISPR transfection into
CAR-T cells. These alterations reduce the potential for GVHD, while simultaneously prolonging
survival of the CAR-T cells, thereby extending their therapeutic window. Studies of the tripleablated cells both in vitro and in vivo demonstrated increased survival relative to wild type (WT)
cells, including when apoptosis was chemically induced18.

Genetic diseases
Because of their ease of access and minimal invasiveness, the integumentary and hematologic
systems are an excellent platform for testing/monitoring experimental CRISPR-Cas therapies.
Epidermolysis Bullosa (EB) is a rare dermatologic condition that yields skin blisters from even
minimal trauma or fiction, with mucous membranes and other organs being involved in some
subtypes. Over 20 different genes have been implicated in EB, and varying combinations of one

14

Clinical CRISPR Outlook

or multiple genes have been identified in EB patients20,21,22. The epidermolysis bullosa
phenotype can manifest as a result of mutated genes that produce dysfunctional proteins, and the
causative mutations can display variable penetrance, with some mutated genes showing
dominant expressivity and others showing recessive expressivity21,22. Previous findings had
demonstrated that grafting autologous skin exhibiting normal phenotypic integrity could provide
symptomatic relief of EB20, but this approach is not feasible for a person with extensive EB.
Recessive dystrophic epidermolysis bullosa (RDEB) is caused by loss-of-function mutation
at a single locus in the gene encoding type VII collogen (COL7A1; C7). Prior attempts at genetic
modification via ZFN and TALEN to treat EB were in various stages of development prior to the
advent of CRISPR-Cas9, which is now considered the more attractive modality for investigating
EB gene therapy. Mutant cells could be treated by CRISPR/Cas with an ex vivo approach of
removing autologous stem cells, correcting the causative mutation in a laboratory, and grafting
the modified cells onto a patient to hopefully introduce WT function. Successful and efficient
restoration of a functional C7 gene for collagen was indeed reported in human keratinocytes via
CRISPR/Cas treatment (Figure 9). The corrected keratinocytes were subsequently bioengineered into skin constructs, which in turn were grafted onto immunodeficient mice. After
successful graft incorporation, the grafted regions were subjected to rigorous in vivo stresses and
skin regeneration testing 21.
The proof of concept reported by Bonafont et al. was essentially reaffirmed, albeit while also
showcasing the remarkable versatility that CRISPR-based gene editing affords. The above
findings report successful grafting of human keratinocytes, but Jackow et al. successfully
corrected C7 and subsequently grafted induced pluripotent stem cells (iPSC), again onto
immunodeficient mice. Successful correction of iSPC s, which exhibit less cellular
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differentiation and consequently are much more versatile, could mark an important milestone in
translating CRISPR-based technologies into the clinic. Normally, iSPCs manipulation is
associated with greater genetic instability relative to manipulation of highly differentiated cells,
but utilization of a high fidelity Cas9 enzyme yielded no discernable off-target effects22. The
resulting iPSC grafts provided long-term safety and efficacy in the immunodeficient mouse
models. These genetic corrections and tissue engineering techniques could represent a
therapeutic option by which patients attain long lasting, even permanent relief from their nonhealing wounds in RDEB. Overall, the most recent studies of this kind offer compelling evidence
for the efficacy and safety of a novel CRISPR/Cas9-based ex vivo gene-editing approach for
clinical treatment of multiple EB subtypes.
Sickle Cell Disease (SCD) and Beta-Thalassemia are the clinical result of mutation in the
Hemoglobin B (HBB) gene, which impairs the functionality of the b-globin subunit in adult
hemoglobin. In SCD, the mutations result in sickle-shaped red blood cells (RBC); in BetaThalassemia, the mutations yield decreased hemoglobin production on RBCs. Consequently,
Beta-thalassemia patients can experience fatigue, bone deformities, and people with SCD suffer
from significant morbidity in the form of severely painful sickle cell crisis attacks and multiorgan damage (due to increased coagulability of sickled RBCs); both conditions are associated
with early mortality. Allogenic transplantation of Hematopoietic Stem Cells (HSC) can be
curative, but also carries the risk of severe toxicity, especially if harvested from a donor with
sub-optimal histocompatibility23.
HBB mutations can theoretically be “corrected” and returned to wild-type by CRISPR-Cas9
editing, but it requires introducing an exogenous donor template and relying on the less-prevalent
HDR pathway, which, again, is not ubiquitously active throughout the cell cycle. Other studies

16

Clinical CRISPR Outlook

have shown that elevated fetal hemoglobin (HbF) production is associated with reduced
morbidity and mortality in both SCD and b-thalassemia, and prior research had demonstrated
induction of HbF production in adults by nullifying regulatory transcription factors
(HBG1/HBG2) that repress HbF production. Métais et al. elected to pursue this promising
avenue of knocking out the HbF inhibitor for treating SCD and Beta-thalassemia patients
because it utilizes constitutively-active NHEJ pathway following Cas-mediated DSB to
effectively inactivate the HbF transcription inhibitor.
A CRISPR-Cas9 sgRNA was designed to target a specific sequence (the BCL11A consensus
motif) in the HBG1/HBG2 gene promoters for the purpose of ablating inhibitory effect of
HBG1/HBG2 on the HbF genetic locus, thereby increasing HbF expression. Human CD34+
hematopoietic stem and progenitor cells (HSPCs) were treated with Cas9:sgRNA-1 RNP
complexes via electroporation to ablate the HSPCs HBG1/HBG2 promoters. In vitro analysis of
edited 34+ HSPCs following electroporation confirmed that gene editing of the HBG1 and
HBG2 gene promoters raised the percentage of both F-cells and HbF protein significantly,
demonstrating viability and efficacy of NHEJ-mediated knock-out of HfB regulator gene
HBG1/HBG2, resulting in increased HfB expression23 (Figure 10).
A nearly identical approach has recently been reported in the news media, in which a woman
has entered into a clinical trial for ex vivo modification of her own HSPC cells to induce
production of fetal hemoglobin HfB, followed by autografting the modified cells for
experimental treatment of her SCD. While the results of this clinical trial have not yet been
published, the recipient of the therapy has participated in interviews with the media, and she
reports subjective symptomatic improvement. Additionally, her physician and research team
report reduced morbidity, improved hemoglobin concentration on blood diagnostics, and
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increased HfB production. A biopsy of this SCD subject s bone marrow cells revealed that 81%
of the collected cells contained the intended genetic change targeted by CRISPR/Cas to induce
fetal hemoglobin production. This finding indicates that edited cells have survived and are
demonstrating long-term expression of HfB. Of note, the clinical trial includes subjects who have
undergone this procedure for treatment of Beta-Thalassemia as well, though no data or anecdotal
reports have been published regarding these cases24.

Materials and Methods:
The research and reviews discussed herein were found primarily using the following search
terms: CRISPR, Cas, Cas9, clinical trials, clinical therapy, Stem cells, iPSC, Epidermolysis
Bullosa, CAR-T cells, antibiotic, antimicrobial, resistance, Sickle Cell Anemia.
The search engines and/or websites utilized in researching this review included: NCBI, also
known as PubMed (ncbi.nlm.nih.gov/), Nature Journals and Communications (nature.com),
Elsevier (elsevier.com), Google Scholar (scholar.google.com), the JAMA Network
(jamanetwork.com), and the Augsburg University Library (lib.augsburg.edu).
Of note: several articles discussed herein were suggested by a website based on previously
viewed pages, and not intentionally sought or discovered via the above search terms.
Additionally, full access to several publications were available for free, but most were obtained
via the Augsburg University Library.
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Discussion:
Ever since the power of CRISPR/Cas was first realized in the laboratory, there has been a
growing hope that its efficient, cost-effective power for altering genes could directly benefit
patients in the clinical setting. Treatments for diverse categories of disease discussed herein –
infectious, genetic, and neoplastic diseases – could one day include some form of CRISPR/Cas
therapy. That hope, while certainly ambitious, is not baseless. While only one subset of diseases
discussed here is explicitly about genetic diseases, multi-drug resistant (MDR) infections and
cancers are also dependent on their underlying genetics. AMR genes and the oncogene-TSG
tandem enable bacteria and cancer, respectively, to evolve into life-threatening illnesses. The
possibility of unleashing a potent gene editing system like CRISPR/Cas against the genes that
potentiate these diseases has inspired research across virtually every specialty in medicine. The
publications discussed herein represent a small fraction of the encouraging progress achieved
thus far, progress that will, hopefully, one day make CRISPR/Cas a viable clinical instrument.

Antimicrobial resistance
The above studies, which focused on silencing AMR genes, show the ability of CRISPR/Cas to
1) target virulent strains of bacteria while sparing avirulent species, 2) selectively target AMR
genes on chromosomes as well as transferrable plasmids, and 3) re-sensitize antimicrobialresistant microbe strains in vivo. While these methods are not yet ready for clinical practice, the
results discussed above are nonetheless promising because, as previously mentioned,
development of novel antimicrobial chemical agents has slowed to a halt, and communityacquired strains of multi-drug resistant strains have been observed in clinical settings.
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As a means of slowing and perhaps reversing the spread of AMR genes, CRISPR/Cas
antimicrobials are one of the most promising avenues currently being explored. When
antimicrobial resistance was first recognized as a growing problem, combination therapy
involving multiple antibiotic classes was touted as a new strategy for slowing the spread of AMR
genes. In theory, combination therapy could disrupt multiple intracellular mechanisms and
compound the drugs bactericidal effects, possibly making the efficacy of the combination
therapy greater than the sum of its parts. However, no improvement in patient mortality was
observed when combination therapies were tested. Antibiotic hybrids25, in which two antibiotics
or an antibiotic and an adjuvant are covalently bonded, are currently being evaluated in clinical
trials, and are showing promising preliminary results in killing MDR bacteria in vivo. However,
the underlying AMR genes remain undisturbed, and it is entirely conceivable that a new
spontaneous mutation could confer resistance to hybrid antibiotics.
Per the United Nations, approximately 700,000 people die from drug-resistant bacterial
infections annually, and estimates by the UN suggest that the death toll could expand to 10
million annually by 2050. To take a broad view of the future of antibiotics, it is the author s
opinion that CRISPR/Cas antimicrobials would yield more sustainable results than a novel
antibiotic or a hybrid antibiotic treatment. Certainly, any breakthrough against drug-resistant
bacteria is good news, regardless of the source, so relying solely on CRISPR/Cas technology
would be imprudent. And bacteria could conceivably develop resistance to any novel antibiotic
drug or technique, including CRISPR/Cas-based AMR destruction. But Cas antimicrobial
enzymes are fundamentally different from traditional antibiotics, and acquiring resistance to
CRISPR/Cas antimicrobials would almost certainly be more difficult than acquiring resistance to
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chemical antibiotics. The work by Liu et al. and Kiga et al. specifically report that bacteria,
when treated with CRISPR/Cas antimicrobials, failed to produce any escape mutants.
A bacterium must spontaneously mutate to negate a traditional antibiotic in the absence of
plasmid-based AMR vectors, but traditional antibiotics are chemically simpler than a
comparatively massive Cas enzyme or CRISPR/Cas-encoding plasmid cassette. Furthermore, the
limited literature reviewed here mentions several possible delivery systems, whereas traditional
antibiotics can only enter through simple or facilitated diffusion. So, eliminating a Cas enzyme
or a delivery cassette would be more difficult than negating a traditional antibiotic, and there are
multiple methods for delivering the CRISPR/Cas anti-AMR products than traditional antibiotics,
so achieving resistance to one delivery may be insufficient for a bacterial population. In short,
spontaneously mutating to adapt to CRISPR/Cas is much more complicated for bacteria than
negating or remove a small antibiotic. Furthermore, because CRISPR/Cas can be programmed to
destroy essentially any AMR gene, the gene effectively dies with the host microbe. Frequently
after a bacterium dies, its plasmids remain intact as do the AMR genes they may carry. This
allows a plasmid to transfer AMR genes to a new strain repeatedly26. This has partially
contributed to the rise of MDR bacteria, and CRISPR/Cas-mediated AMR gene destruction is the
first system to directly destroy the underlying AMR genes and thereby end their continuous
propagation.
In recent years, multiple studies have demonstrated the importance of a healthy microbiome
with a diverse normal flora microbe population. One modern example demonstrating the
importance of a healthy microbiome involves clostridium difficile infections. Antibiotics do not
discern between virulent and avirulent bacteria, so a patient completing a course of antibiotics
almost certainly will kill a percentage of their avirulent normal flora. When a person s normal
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homeostasis within the microbiome is disrupted by mass antibiotic-induced death, bacteria such
as C. Diff can fill the microbial void, potentially leading to a serious intestinal C. diff infection.
With that in mind, the findings discussed here that demonstrated antimicrobial CRISPR/Cas
activity while sparing the normal flora are encouraging.
Delivering the CRISPR/Cas system in vivo remains a major obstacle for clinical utilization
and is currently the subject of ongoing research. Kiga et al. and Liu et al. reported encouraging
results demonstrating increased in vivo survival in their wax moth larvae and mice experiments,
respectively, but translating that into human populations will absolutely be a challenge.

Cancer therapy
Correcting the mutations driving cancerous growths – or altering the immune system to
recognize an evolving neoplasm – are exciting strategies for cancer therapy, and the
CRISPR/Cas system is uniquely equipped to develop these strategies into a clinical reality. The
novel findings of TERT suppression, and associated failure of tumor cells to grow on
immunodeficient mice, is an exciting finding given how prevalent TERT activation is in cancer.
Preventing cancer immortalization via telomerase ablation could be a powerful adjunct to, or
replacement for, chemotherapy. Deactivating Telomerase in somatic cells in vivo, however, is
significantly more difficult than the ex vivo xenograft recounted in this review; future
investigations for achieving Telomerase inactivation with an in vivo strategy will almost
certainly be explored.
Several studies have been published since 2017 regarding the promise of CAR-T therapy as a
new cancer treatment. Ren et al. successfully demonstrated CRISPR/Cas-mediated knock out of
CAR-T cell surface proteins that would normally create risk for GVHD (CD3 and HLA-1).
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Additionally, a new strategy for creating long-term viability of CAR-T cells post-transfusion was
identified by CRISPR/Cas-mediated knockout of the apoptosis-promoting Fas gene, and CAR-T
cells demonstrated a longer active lifespan as an in vivo xenograft following successful
inactivation of Fas. What s more, they were able to accomplish a triple knockout (CD3, HLA-1,
and Fas) in one fell swoop by packaging the CRISPR system with multiple sgRNAs. As more
sgRNAs are co-introduced with a Cas enzyme into a cell, there is greater theoretical potential for
off-target effects. No such off-target effects were reported, however. Taken together, these
findings demonstrate the power, versatility, and efficiency that CRISPR/Cas gene editing affords
a researcher, and further illustrate the potential for clinical CRISPR utilization.
Current cancer therapies generally fall into three categories: surgical excision of a tumor
mass, radiation therapy, and chemotherapy15. These therapies can absolutely be successful
individually and in concert, but they are not without drawbacks. Surgical excision involves
cutting out as much of a tumor mass as possible, but it s simply impossible to remove every
cancer cell in surgery. Radiation Therapy aims to destabilize the genome of a cancer cells via
directly exposing a cancerous mass to ionizing radiation, but non-cancerous cells are inevitably
caught in the crossfire. Finally, chemotherapy is a systemic infusion of medications that
preferentially attack cancer cells, but, once again, non-cancerous dividing/active cells are also
damaged. Each method has been honed and improved over time, of course, but their
shortcomings remain.
The above studies demonstrate how CRISPR/Cas-based cancer therapy could better
discriminate between cancer and healthy cells. As previously mentioned, telomerase is only
active in cancerous somatic cells, so disrupting TERT – and by extension, telomerase – would
only adversely affect cancer cells. Given how frequently active TERT is found in cancer cells, its
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inactivation as described by Ren et al. could evolve into a new therapy against cancer. Similarly,
CAR-T cells that selectively target tumor-associated antigens could additionally aid in
eradicating cancer cells while minimizing toxicity and side effects to the patient. Moreover, the
work to create an “off the shelf” allogenic CAR-T cell therapy could expedite treatment
following new cancer diagnosis, and CAR-T cells are currently being developed to specifically
target cancer cells alone and minimize damage to healthy cells. Surgical resection, radiation
therapy, and chemotherapy will likely always have a place in cancer therapy, but CRISPR/Cas
utilization to knockout TERT and hone CAR-T cells could develop into powerful complimentary
therapies.

Genetic conditions
The EB research recounted here represent some of the most promising findings for CRISPR/Cas
as a therapeutic implement. Since Hirsch et al. first described autografting unaffected dermis to
achieve symptomatic relief, the strategy in the field has involved variations of an ex vivo
modification strategy, in which incorporation of a functional WT gene replaces the mutant
protein in EB patients. Multiple studies since have created EB-corrected skin constructs which
were successfully grafted onto immunodeficient mice. Moreover, Jackow et al. demonstrated
successful CRISPR/Cas-mediated gene correction in iPSC s. This represents a monumental
achievement, as iPSCs and PSCs are versatile and can differentiate into numerous specialized
cells. These are promising steps towards clinical reality, but some barriers remain. Successful
fusion of the graft onto a human dermal basement membrane has not yet been demonstrated and,
as always, ensuring no harmful off-target effects is key. Techniques to refine the ex vivo
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correction strategies, or potentially developing new in vivo approaches, are worth exploring for
future research.
As previously mentioned, there is currently an ongoing clinical trial in which CRISPR/Cas
successfully deactivated an inhibitory transcription factor against fetal hemoglobin to increase
serum HbF and relieve SCD symptoms. While no peer-reviewed published data is available, lab
findings and the subjective accounts from the subjects and their physicians are encouraging. As
reported by NPR, researchers had hoped to achieve 20% HfB hemoglobin expression in studies
following the treatment, but early results show the subject consistently expressing HfB over
40%24. Of note, the subject has reported that the pain associated with SCD has improved since
she underwent treatment in June 2019, and has required less narcotic analgesia for controlling
her pain24. Fewer details regarding the Beta-Thalassemia patients was available, but they have
reportedly required less frequent blood transfusions since undergoing treatment with
CRISPR/Cas-altered progenitor cells. If the subjects symptoms and biomarkers persistently
demonstrate improvement in key parameters, such findings would represent a monumental step
forward for CRISPR/Cas technology, and exhibit the safety and therapeutic power of
CRISPR/Cas gene therapy to the medical community at large.
Current treatments for most genetic diseases currently center on symptomatic treatment and
minimizing complications. EB, for example, with its characteristic painful blistering/sloughing
of skin and reduced skin integrity, leaves a person vulnerable to infection and chronic pain, so
current therapies include prophylactic antibiotics, topical skin treatments, and skin grafting in
appropriate candidates. Similarly, SCD and Beta-Thalassemia treatments involve controlling and
minimizing symptoms with medications and blood transfusions.
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Gene therapy involving permanent correction of a mutation at the genetic level would
achieve chronic expression of the corrected gene, which would, in theory, be curative for the
genetic condition in all treated cells and their progeny. There are genetic diseases for which
organ or bone marrow transplants can effectively be curative, but numerous incurable genetic
diseases remain. This promise of gene therapy explains why CRISPR/Cas has received so much
attention in both the laboratory and the public consciousness. Effective and safe gene therapy in
a human subject, no matter what system, is an unmitigated success, and ZFN and TALEN
systems have both demonstrated some efficacy in gene therapy clinical trials. But relative to
ZFN and TALEN gene-editing techniques, CRISPR/Cas is more affordable, more easily
programmable, exhibits superior specificity and, as reported in the above literature review, has
shown great promise with in vivo experiments and in clinical trials. In short, CRISPR/Cas
achieves higher fidelity editing with lower costs and appears situated as the primary candidate
for creating clinically relevant gene therapies going forward.

Future Directions
The practical outlook of CRISPR/Cas therapy is promising, but several hurdles remain, including
achievement of in vivo delivery and minimizing off-target effects. Initially, there was promise
that viral delivery of CRISPR/Cas constructs may enable extensive in vivo delivery, like the
bacteriophage or phagemid delivery systems described here for CRISPR/Cas delivery into
bacteria. Progress has also been made with Ribonucleoprotein delivery, in which the transcribed
CRISPR/Cas system is delivered in the form of mRNA, may be the best vector for continued
pursuit of clinical CRISPR applications as they can be modified to recognize tissue-specific cell
surface proteins, potentially enabling efficient targeting of a cell type in vivo11. To minimize off-
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target effects, several high-fidelity modified Cas isoforms have been described and utilized in
human cells in vitro, with more modified Cas variants in development27. However, there are no
reports available describing any ex vivo-type experiment like the studies described here.
CRISPR/Cas has entered the zeitgeist in the research community because, in addition to its
cost-effectiveness, it yields fewer unwanted indels relative to ZFN and TALEN editing
techniques. However, the risk of off-target genetic effects still requires mitigation before
CRISPR/Cas-based gene therapy utilization can be expanded5,28.

Conclusions:
CRISPR/Cas has, in a few short years, developed from a little-studied microbial curiosity into an
indispensable scientific tool that is driving discovery and creating new methods of treating
disease. The ease with which CRISPR/Cas can be reprogrammed enables it to target any desired
DNA sequence, meaning that genetic diseases, infectious diseases, and cancer can all
theoretically be treated by well-controlled alterations of the underlying genes that cause, enable,
or fail to prevent a given disease. That is why the scientific community is so excited about
CRISPR/Cas: It has the potential to treat diseases that appear categorically different, because
their root causes are genetic in nature. Clinical trials involving gene alterations have increased
substantially since CRISPR/Cas was first described as an efficient gene editor, and scientists are
consistently finding new ways to utilize this powerful system.
Before it can enter the clinic in earnest, however, ethical ramifications and considerations of
CRISPR/Cas require thorough discussion and debate. The studies and therapies discussed
throughout this report have centered on altering genes of somatic cells, the results of which are
not passed on to subsequent generations. But the hypothetical editing of germ-line cells could
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potentially be retained in all subsequent progeny. Additionally, it is entirely possible that a child
with a genetic disease, perhaps EB or Duchene Muscular Dystrophy, may benefit from early
correction of the disease-causing gene. There are numerous ethical dilemmas to consider before
rolling out CRISPR/Cas. Is it ethical to edit the genome of nascent embryo? In what conditions,
if any, are genetic modifications appropriate in a patient who has not reached the age of consent,
or who is unable to consent? When is gene editing cosmetically indicated, if ever? And of
course, as an issue of justice, how do institutions minimize or, ideally, eliminate socioeconomic
barriers that would prevent people who are impoverished or otherwise disenfranchised, from
receiving gene therapy?
These questions are not just hypotheticals. In 2018, an experiment by He Jiankui out of
Southern University of Science and Technology in Shenzhen, China reported the first
CRISPR/Cas-mediated editing of human embryos29. To briefly recap the study s purpose, the
CRISPR/Cas alteration reported by He was meant to reduce the embryos risk of contracting
HIV, as the eggs were extracted from an HIV positive woman prior to in vitro fertilization, and
the woman was set to have the embryo transferred into her uterus. The edited embryo ultimately
progressed normally and developed into two healthy females that were born at full term. There
were clear issues with the experiment, and no definitive evidence exists demonstrating that He
actually succeeded in editing the targeted genes. The experiment was almost universally decried
by the scientific community as a reckless exercise, but the outcry doesn t change the irreversible
germ-line mutations that He supposedly achieved. Permanently altering the genes of two girls
was unethical, impulsive, and irresponsible, but none of these ethical concerns stalled He s
research. The flaws and failures of He s experiment show that, without proper involvement and
guidance of bioethicists, the public won t readily trust CRISPR/Cas as a powerful tool for good.
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The CRISPR/Cas system appears likely to yield novel therapies, and could aid in treating
diseases discussed here, as well as some not previously considered in this report. The studies
discussed herein showcase the diverse panoply of diseases that are candidates for CRISPR/Casbased therapy, despite having fundamental differences in etiology and disease course. As a
research tool, CRISPR has proven itself to be a modern scientific essential, and the findings
reviewed here, in which a diverse array of diseases are considered candidates for CRISPS/Cas
treatment, provide promise for the future of therapeutic CRISPR/Cas utilization.

29

Clinical CRISPR Outlook

References:
1.

Li H, Yang Y, Hong W, Huang M, Wu M, Zhao X. Applications of genome editing
technology in the targeted therapy of human diseases: mechanisms, advances and
prospects. Signal Transductal Target Ther. 2020;5(1). doi:10.1038/s41392-019-0089-y

2.

Rath D, Amlinger L, Rath A, Lundgren M. The CRISPR-Cas immune system: Biology,
mechanisms and applications. Biochimie. 2015;117:119-128.
doi:10.1016/j.biochi.2015.03.025

3.

Lo TW, Pickle CS, Lin S, et al. Precise and heritable genome editing in evolutionarily
diverse nematodes using TALENs and CRISPR/Cas9 to engineer insertions and deletions.
Genetics. 2013;195(2):331-348. doi:10.1534/genetics.113.155382

4.

Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable
dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science.
2012;337(6096):816-821. doi:10.1126/science.1225829

5.

Hirakawa MP, Krishnakumar R, Timlin JA, Carney JP, Butler KS. Gene editing and
CRISPR in the clinic: Current and future perspectives. Biosci Rep. 2020;40(4).
doi:10.1042/BSR20200127

6.

Li X, Heyer W-D. Homologous recombination in DNA repair and DNA damage
tolerance. Cell Res. 2008;18(1):99-113. doi:10.1038/cr.2008.1

7.

Krejci L, Altmannova V, Spirek M, Zhao X. Homologous recombination and its
regulation. Nucleic Acids Res. 2012;40(13):5795-5818. doi:10.1093/nar/gks270

8.

O Kane GM, Connor AA, Gallinger S. Characteri ation, Detection, and Treatment
Approaches for Homologous Recombination Deficiency in Cancer. Trends Mol Med.
2017;23(12):1121-1137. doi:10.1016/j.molmed.2017.10.007

9.

Orthwein A, Noordermeer SM, Wilson MD, et al. A mechanism for the suppression of
homologous recombination in G1 cells. Nature. 2015;528(7582):422-426.
doi:10.1038/nature16142

10.

Liu H, Li H, Liang Y, et al. Phage-delivered sensitisation with subsequent antibiotic
treatment reveals sustained effect against antimicrobial resistant bacteria. Theranostics.
2020;10(14):6310-6321. doi:10.7150/thno.42573

11.

Xu X, Hulshoff MS, Tan X, Zeisberg M, Zeisberg EM. Crispr/cas derivatives as novel
gene modulating tools: Possibilities and in vivo applications. Int J Mol Sci. 2020;21(9).
doi:10.3390/ijms21093038

12.

Citorik RJ, Mimee M, Lu TK. Sequence-specific antimicrobials using efficiently delivered
RNA-guided nucleases. Nat Biotechnol. 2014;32(11):1141-1145. doi:10.1038/nbt.3011
30

Clinical CRISPR Outlook

13.

Bikard D, Euler CW, Jiang W, et al. Exploiting CRISPR-cas nucleases to produce
sequence-specific antimicrobials. Nat Biotechnol. 2014;32(11):1146-1150.
doi:10.1038/nbt.3043

14.

Kiga K, Tan XE, Ibarra-Chávez R, et al. Development of CRISPR-Cas13a-based
antimicrobials capable of sequence-specific killing of target bacteria. Nat Commun.
2020;11(1):1-11. doi:10.1038/s41467-020-16731-6

15.

Cleal K, Norris K, Baird D. Telomere length dynamics and the evolution of cancer
genome architecture. Int J Mol Sci. 2018;19(2):1-17. doi:10.3390/ijms19020482

16.

Weinberg RA, The Biology of Cancer. 2nd ed. New York, N.Y.: Garland Science; 2014.

17.

Wen L, Zhao C, Song J, et al. CRISPR/Cas9-Mediated TERT Disruption in Cancer Cells.
Int J Mol Sci. 2020;21(2):653. doi:10.3390/ijms21020653

18.

Ren J, Zhang X, Liu X, et al. A versatile system for rapid multiplex genome-edited CAR
T cell generation. Oncotarget. 2017;8(10):17002-17011. doi:10.18632/oncotarget.15218

19.

Mollanoori H, Shahraki H, Rahmati Y, Teimourian S. CRISPR/Cas9 and CAR-T cell,
collaboration of two revolutionary technologies in cancer immunotherapy, an instruction
for successful cancer treatment. Hum Immunol. 2018;79(12):876-882.
doi:10.1016/j.humimm.2018.09.007

20.

Hirsch T, Rothoeft T, Teig N, et al. Regeneration of the entire human epidermis using
transgenic stem cells. Nature. 2017;551(7680):327-332. doi:10.1038/nature24487

21.

Bonafont J, Mencía Á, García M, et al. Clinically Relevant Correction of Recessive
Dystrophic Epidermolysis Bullosa by Dual sgRNA CRISPR/Cas9-Mediated Gene
Editing. Mol Ther. 2019;27(5):986-998. doi:10.1016/j.ymthe.2019.03.007

22.

Jacków J, Guo Z, Hansen C, et al. CRISPR/Cas9-based targeted genome editing for
correction of recessive dystrophic epidermolysis bullosa using iPS cells. Proc Natl Acad
Sci U S A. 2019;116(52):26846-26852. doi:10.1073/pnas.1907081116

23.

Métais JY, Doerfler PA, Mayuranathan T, et al. Genome editing of HBG1 and HBG2 to
induce fetal hemoglobin. Blood Adv. 2019;3(21):3379-3392.
doi:10.1182/bloodadvances.2019000820

24.

Stein R. A Year In, 1st Patient to Get Gene Editing for Sickle Cell Disease Is Thriving;
NPR News; June 23, 2020. Accessed June 27, 2020. https://www.npr.org/sections/healthshots/2020/06/23/877543610/a-year-in-1st-patient-to-get-gene-editing-for-sickle-celldisease-is-thriving

31

Clinical CRISPR Outlook

25.

Wencewicz TA. Crossroads of Antibiotic Resistance and Biosynthesis. J Mol Biol.
2019;431(18):3370-3399. doi:10.1016/j.jmb.2019.06.033

26.

Lerminiaux NA, Cameron ADS. Horizontal transfer of antibiotic resistance genes in
clinical environments. Can J Microbiol. 2019;65(1):34-44. doi:10.1139/cjm-2018-0275

27.

He X, Wang Y, Yang F, et al. Boosting activity of high-fidelity CRISPR/Cas9 variants
using a tRNAGln-processing system in human cells. J Biol Chem. 2019;294(23):93089315. doi:10.1074/jbc.RA119.007791

28.

Alagoz M, Kherad N. Advance genome editing technologies in the treatment of human
diseases: CRISPR therapy (Review). Int J Mol Med. 2020:521-534.
doi:10.3892/ijmm.2020.4609

29.

Cyranoski, D. The CRISPR-bab scandal: hat s ne t for h man gene-editing; Nature;
February, 2019, accessed July 30, 2020. https://www.nature.com/articles/d41586-01900673-1; doi: 10.1038/d41586-019-00673-1.

32

Clinical CRISPR Outlook

Supplemental Figures

Figure 1: A structural schematic of CRISPR/Cas riboprotein. The Cas enzyme is the large blue
object, dsDNA exit either side of the upper half. Within the Cas enzyme, DNA unwinds and one
strand hybridizes with complimentary guide RNA. Guide RNA is comprised of either crRNA
and tracrRNA in tandem (left) or a sgRNA (Right) which essentially combines the crRNA and
tracrRNA with a hairpin loop structure. The target gene on the DNA sequence is highlighted in
white within the cas protein, and the site of Cas-mediated DSB induction is denoted with black
arrows.3

Figure 2: Innate DNA repair mechanisms that guide gene editing. Formation of a DSB to initiate
DNA repair by either NHEJ to yield indel events (top path) or HDR, which uses a template DNA
strand for repair (bottom path).28
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Figure 3: Structures of ZFN, TALEN, and
CRISPR/Cas nucleases. Both ZFN and TALEN
feature a Fok1 restriction enzyme that induces DSBs
within non-specific nucleotide sequences, leaving
behind a 5 tail. Specificity for ZFN-mediated
cleavage is accomplished with unique Zinc Finger
protein motifs, that bind nucleotides triplets around
the desired cut site. A unique TALE protein
sequence likewise guides Fok1 to the desired
sequence in the TALEN system by binding single
nucleotides. Unlike TALEN and ZFN systems that
utilize protein-based guides, a guide RNA sequence
enables Cas-mediated DSBs in the CRISPR/Cas
system.11

Figure 4: Delivering a phagemid-based anti-AMR CRISPR/Cas construct. The phagemidpackaged CRISPR/Cas sequence is programmed to target two distinct plasmids (pUSA01 and
pUSA02) simultaneously. pUSA02 confers Tetracycline resistance. Bacterial colonies were
plated on either a normal agar or on a tetracycline (Tet) selection medium after treatment with a
non-targeting CRISPR/Cas construct or a CRISPR/Cas targeting the tetracycline resistance
plasmid pUSA02.13

34

Clinical CRISPR Outlook

Figure 5: solid lines represent the growth curves of the Kanamycin-resistant strain treated with:
PRESA strategy, Lytic Phage, CRISPR/Cas targeting Kanamycin resistance alone (vB_Cas9),
and Kanamycin (Kan), as well as an untreated control. Additionally, some plates were inoculated
with both two E. Coli strains, one with Kanamycin resistance and one lacking kanamycin
resistance (MG1655), which is represented as a dotted orange line.10

Figure 6: Therapeutic effect of CRISPR/Cas using in vivo Galleria Mellonella infection model.
Administration of anti-resistance CRISPR/Cas (EC-CapsidCas13a-blaIMP-1) into G. Mellonella
larvae infected with Carbapenem-resistant E. Coli isolates significantly improved host survival
when compared with both a non-treatment group and a non-targeting CRISPR/Cas construct
treatment group.14
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Figure 7: Telomere structure. The telomere is comprised of a repeating 5 -TTAGGG-3
nucleotide motif, stabilized by various proteins. There is a 3 overhang with this motif, and it
circles back to self-invade an upstream telomere sequence to form a stable t-loop that effectively
caps off both ends of every chromosome.16

Figure 8: TERT knockout xenograft on mice. xenotransplant of both WT Hela cells (WTPE)
and TERT monoallelic knock-out Hela cells (TERT+/-) grafted to mouse left and right hind legs,
respectively. Table summarizes xenotransplant results; all WTPE grafts developed into tumors,
while TERT+/- grafts yielded no tumors.17
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Figure 9: Collagen VII (C7) expression in RDEB keratinocytes. Keratinocytes were either
untreated (A, top left), or treated with varying CRISPR/Cas sgRNA combinations to correct C7
gene, and expression was qualified via immunofluorescence. Western blot analyses
demonstrating (B) C7 expression in RDEB keratinocytes following CRISPR/Cas treatment with
varying combinations of sgRNAs, compared with untreated keratinocytes (P1) and healthy
human keratinocytes (HK) and (C) from collected culture supernatant, demonstrating secretion
of C7 after CRISPR/Cas-based correction.21

Figure 10: Inducing Fetal Hemoglobin expression. Following transfection with CRISPR/Cas
construct targeting a HbF inhibitory TF, cells exhibit (left) substantial increase in HbF
expression and (middle) an increase in %HbF in CD235a1 erythroblasts isolated from recipient
bone marrow. Additionally, the correlation of the %indels with the %HbF in CD235a1
erythroblasts isolated from recipient bone marrow (right) is illustrated.23
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